Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400836 | 0.90 | EPHX1 (0.54) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL1354525 | 0.84 | HDAC4 (0.51) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL2466962 | 0.84 | CES2 (0.64) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL1354521 | 0.84 | HDAC4 (0.51) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL3711116 | 0.83 | SRC (0.58) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL7463303 | 0.82 | EPHX1 (0.50) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL7278958 | 0.82 | EPHX1 (0.50) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL30631966 | 0.82 | EPHX1 (0.50) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| SCHEMBL3886825 | 0.82 | EPHX1 (0.50) | HDAC4HDAC7HDAC5EPHX1PARP1 | |
| Hydrochloric Acid SCHEMBL27769803 | 0.81 | EPHX1 (0.49) | HDAC4HDAC7HDAC5EPHX1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | HDAC4 2230/4885HDAC7 2436/4885HDAC5 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.